Dynamic quotes: Off
|
Company Description (as filed with the SEC)
We are a biopharmaceutical company developing targeted therapies for the treatment of cancer and inflammatory diseases. We use our proprietary technology to create novel small molecule drug conjugates, or SMDCs, and companion imaging diagnostics. Our SMDCs actively target receptors that are over-expressed on diseased cells, relative to healthy cells. This targeted approach is designed to enable the treatment of patients with highly active drugs at greater doses, delivered more frequently, and over longer periods of time than would be possible with the untargeted drug alone. We are also developing companion imaging diagnostics for each of our SMDCs that are designed to identify the patients whose disease over-expresses the target of the therapy and who are therefore more likely to benefit from treatment. ... More ...
Analyst Info |
|
| Annual EPS Est: | $-0.45 |
| Quarterly EPS Est: | -0.09 |
| PEG Ratio: | -.03 |
|
Mean Recommendation: View Summary / View All |
1.5 |
Data is provided by Zacks Investment Research

